文献速递中毒与环境急症复苏、休克与脓毒症重症综合管理与镇静镇痛

Sentanyl:非致命性过量后血芬太尼浓度与纳洛酮剂量的比较

Sentanyl: a comparison of blood fentanyl concentrations and naloxone dosing after non-fatal overdose.
PubMed 文献 · Clin Toxicol (Phila) · 2021-07-19
一句话结论急诊非致命性阿片过量幸存者中,血芬太尼浓度与逆转呼吸抑制所用纳洛酮剂量无相关性,合并镇静催眠药暴露者芬太尼浓度更低但纳洛酮用量相近。

该先导研究纳入急诊就诊、因呼吸抑制需纳洛酮逆转的成人阿片过量患者20例,采血行全面毒物检测(芬太尼及类似物、纳洛酮定量,常见镇静催眠药等筛查),比较有无合并镇静催眠药暴露者的血芬太尼浓度与纳洛酮剂量。95%(19/20)检出芬太尼暴露,无药用芬太尼报告,3份检出乙酰芬太尼或卡芬太尼;芬太尼暴露者血浓度<0.1–19 ng/mL,均值6.2 ng/mL,中位数3.6 ng/mL。芬太尼浓度与逆转所用纳洛酮剂量无关系;9例检出镇静催眠药(含苯二氮䓬类、肌松剂、抗抑郁药),其芬太尼浓度更低但纳洛酮用量与无合并暴露者相似。结果提示耐受性与合并用药影响阿片过量的发生与复苏管理。

要点

  • 因呼吸抑制需纳洛酮逆转的急诊成人阿片过量患者中,95%(19/20)血中检出芬太尼暴露,无人报告药用芬太尼使用。
  • 芬太尼暴露者血药浓度<0.1–19 ng/mL,均值6.2 ng/mL,中位数3.6 ng/mL,浓度与所用纳洛酮剂量无相关性。
  • 9例合并镇静催眠药(苯二氮䓬类、肌松剂、抗抑郁药等)暴露者芬太尼浓度更低,但纳洛酮剂量与无合并暴露者相似。
  • 3份标本检出芬太尼类似物乙酰芬太尼或卡芬太尼,提示需警惕高效类似物暴露。
  • 纳洛酮用量不能据血芬太尼浓度预判,耐受与合并用药影响过量发生与复苏。

适用人群与场景

  • 纳入:到急诊就诊、因过量需纳洛酮逆转呼吸抑制、且临床需静脉采血或建立静脉通路的成人患者(先导研究,n=20份血标本)。
  • 场景:急诊科(ED);病情阶段为院前过量后到院、已用纳洛酮逆转呼吸抑制的非致命性过量幸存者。
  • 原文未提及明确的排除标准及儿科、产科等特殊人群。

诊断标准与关键阈值

  • 原文未提及具体的诊断标准、评分界值或纳洛酮启动/停止阈值;入组条件为需纳洛酮逆转呼吸抑制的临床判断。
  • 毒物检测为全面毒理学检测,含芬太尼、芬太尼类似物与纳洛酮定量,以及常见镇静催眠药和多种违禁及药用物质检测。

处置流程与药物剂量

  • 原文未提及具体的纳洛酮剂量、给药途径、频次或疗程方案;仅记录为逆转呼吸抑制所给纳洛酮剂量并与血芬太尼浓度比较。
  • 原文未提及针对芬太尼类似物或合并镇静催眠药暴露的特殊处置步骤。

红旗征与不能漏的情况

  • 合并镇静催眠药(苯二氮䓬类、肌松剂、抗抑郁药)暴露:原文显示该组芬太尼浓度更低而纳洛酮用量相似,提示合并暴露影响过量表现与复苏。
  • 芬太尼类似物乙酰芬太尼或卡芬太尼检出(3份标本):原文强调此类高效物质可在生物标本中呈低浓度,需警惕。
  • 原文未提及需立刻处理或不能漏诊的具体红旗征及其处理。

研究设计与关键结果

  • 研究类型:先导研究(pilot study),单中心急诊,样本20份血标本,无对照组随机化设计。
  • 人群与干预:成人因过量需纳洛酮逆转呼吸抑制且需静脉采血者,采血行全面毒理学检测,比较芬太尼浓度与纳洛酮剂量。
  • 主要结果:19/20(95%)检出芬太尼暴露,余1例 heroin 代谢物阳性;无人报告药用芬太尼;3份检出乙酰芬太尼或卡芬太尼;11例仅检出芬太尼及其代谢物为唯一阿片类。
  • 浓度:芬太尼暴露者血浓度<0.1–19 ng/mL,均值6.2 ng/mL,中位数3.6 ng/mL;芬太尼浓度与纳洛酮剂量无关系。
  • 合并暴露:9例检出镇静催眠药,其芬太尼浓度更低但纳洛酮剂量与无合并暴露者相似。
  • 原文未给出效应量、95%CI、P值、关键次要终点的量化结果及不良事件数据。

证据类型、等级与局限

  • 证据类型:先导研究(pilot study),观察性设计,非RCT。
  • 局限:样本小(n=20份血标本)、单中心、观察性、无随机对照,结果需前瞻性验证;原文未给出证据等级或推荐强度。

对床旁实践的改变

  • 提示纳洛酮剂量不应依据推测的血芬太尼浓度决定,因二者在本研究中无相关性;纳洛酮仍应按临床呼吸抑制逆转需要滴定(原文未给具体方案)。
  • 对需纳洛酮逆转的急诊阿片过量患者,应考虑到芬太尼类似物及合并镇静催眠药暴露的可能,合并暴露者表现与复苏反应可能不同。
  • 不适用:本结果来自20例单中心先导研究,不能外推为所有阿片过量人群的剂量阈值或通用推荐;原文未给出可改变的纳洛酮具体剂量做法。

指南或共识出处

  • 原文未提及指南或共识名称;来源期刊为 Clin Toxicol (Phila)。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

INTRODUCTION: Non-pharmaceutical fentanyl and its analogs have driven striking increases in opioid-associated overdose deaths. These highly potent opioids can be found at low concentrations in biological specimens. Little is known regarding the concentrations of these substances among survivors of non-fatal overdoses. In a locale where fentanyl is responsible for the majority of non-fatal opioid overdoses, we compared the concentration of fentanyl in blood to naloxone dosing in the presence and absence of a concurrent sedative-hypnotic exposure.

METHODS: In this pilot study, we enrolled adult patients presenting to the emergency department (ED) who: (1) arrived after an overdose requiring naloxone for the reversal of respiratory depression; and (2) who required venipuncture or intravenous access as part of their clinical care. Blood specimens (n = 20) underwent comprehensive toxicology testing, including the quantitation of fentanyl, fentanyl analogs, and naloxone, as well as the detection of common sedative-hypnotics and a wide range of other illicit and pharmaceutical substances. We then compared fentanyl concentrations to naloxone dosing in participants with and without a concomitant sedative-hypnotic exposure.

RESULTS: Nineteen of twenty participants (95%) were exposed to fentanyl prior to their overdose; the remaining participant tested positive for heroin metabolites. No participants reported pharmaceutical fentanyl use. Fentanyl analogs - acetylfentanyl or carfentanil - were present in three specimens. In 11 cases, fentanyl and its metabolites were the only opioids identified. Among the fentanyl-exposed, blood concentrations ranged from <0.1-19 ng/mL with a mean of 6.2 ng/mL and a median of 3.6 ng/mL. There was no relationship between fentanyl concentration and naloxone dose administered for reversal. We detected sedative-hypnotics (including benzodiazepines, muscle relaxants, and antidepressants) in nine participants. Among the sedative-hypnotic exposed, fentanyl concentrations were lower, but naloxone dosing was similar to those without a concomitant exposure.

CONCLUSIONS: In this study, we found that: 1) fentanyl was present in the blood of nearly all participants; 2) fentanyl concentrations were lower among study participants with concomitant sedative-hypnotic exposure; and 3) the dose of naloxone administered for overdose reversal was not associated with the measured fentanyl concentration in blood specimens. Our results underscore the role that tolerance and concomitant drug exposure play in the precipitation and resuscitation of management of opioid overdose.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Krotulski AJ, Chapman BP, Marks SJ, et al. Sentanyl: a comparison of blood fentanyl concentrations and naloxone dosing after non-fatal overdose. Clin Toxicol (Phila). 2021. PMID: 34278904. doi:10.1080/15563650.2021.1948558

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。